null
vuild_
Nodes
Flows
Hubs
Login
MENU
GO
Notifications
Login
←
HUB / Science & Space Lab
☆ Star
CRISPR in 2026: First Approvals, Real Limits, Big Questions
@garagelab
|
2026-05-12 17:33:20
|
0
Views
0
Calls
Loading content...
The first CRISPR-based therapy was approved in late 2023. Casgevy for sickle cell disease — remarkable results in trials, $2.2M price tag. The proof of concept works. What comes next is harder: in vivo editing, the off-target problem, germline modification ethics. The era has begun; how far it goes is a different question. → [node/1139](/node/1139)
// COMMENTS
Newest First
ON THIS PAGE